All Posts
Review | Cardiometabolic comorbidities in cancer survivors.
19 Jul, 2022 | 13:17h | UTCCardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review
Nutrition state of science and dementia prevention.
19 Jul, 2022 | 13:11h | UTCCommentary: Improving research on diet and dementia – Keck School of Medicine of USC
M-A of RCTs | Effects of acetaminophen and ibuprofen monotherapy in febrile children.
19 Jul, 2022 | 13:15h | UTC
Cross Sectional Study | Variation in population attributable fraction of dementia associated with potentially modifiable risk factors by race and ethnicity in the US.
19 Jul, 2022 | 13:08h | UTCCommentaries:
12 Risk Factors Linked to Dementia Could Be Modified, Reduce US Cases by 400,000 – HCP Live
Hypertension, obesity, physical inactivity among highest risk factors for dementia – Healio
Commentary on Twitter
Number of people w/dementia is growing worldwide; this article identifies 12 modifiable risk factors accounting for~ 40% of people w/dementia. Hypertension most imp, followed by obesity and physical inactivity. https://t.co/mD5lrqZTyf @JAMANetworkOpen Kudos @PLutsey & team. pic.twitter.com/LG5LjFHqV6
— Harlan Krumholz (@hmkyale) July 7, 2022
In this cross-sectional study, a large fraction of dementia cases in the US were associated with potentially modifiable risk factors, especially for Black and Hispanic individuals. https://t.co/v6g2HPNLpR
— JAMA Network Open (@JAMANetworkOpen) July 6, 2022
Single arm phase 2 study | Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for hematopoietic stem cell transplantation.
19 Jul, 2022 | 13:00h | UTCLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma – MedPage Today (free registration required)
Related:
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Lisocabtagene maraleucel as second-line therapy in adults with R/R large B-cell #lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study https://t.co/NwkfPmVHu0 #lymsm pic.twitter.com/jHj5rFadV2
— The Lancet Oncology (@TheLancetOncol) July 13, 2022
RCT | Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis.
19 Jul, 2022 | 13:06h | UTCTreat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Commentary: TNF inhibitor tapered T2T strategy feasible in PsA and axSpA – medwireNews
Commentary on Twitter
Treat-to-target (#T2T) tapering strategy is an effective and safe alternative to a T2T full dose continuation strategy in patients with #psoriatic #arthritis and axial #spondyloarthritis with stable low disease activity using TNF inhibitorshttps://t.co/YhurbawiTm pic.twitter.com/1jj4zuYkPf
— Annals of the Rheumatic Diseases (@eular_ARD) June 18, 2022
Phase 2 RCT | Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma.
19 Jul, 2022 | 12:58h | UTCDeintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentaries:
Commentary on Twitter
Less is more? 🤔 2-cycle cisplatin concurrent chemoradiotherapy is not inferior to 3-cycles based on 3-yr PFS in treating locoregionally advanced nasopharyngeal ca w/preRX EBV DNA levels < 4000.QOL & toxicity improved w/ less chemo https://t.co/XovHi2P06W pic.twitter.com/JJqiC8wnWW
— Journal of Clinical Oncology (@JCO_ASCO) January 25, 2022
RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
19 Jul, 2022 | 12:57h | UTCZanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Zanubrutinib Wins in First-Line CLL for Older Patients — The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial – MedPage Today (free registration required)
EASL Clinical Practice Guidelines on hemochromatosis.
18 Jul, 2022 | 11:47h | UTCEASL Clinical Practice Guidelines on haemochromatosis – Journal of Hepatology
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.
18 Jul, 2022 | 11:49h | UTC
Commentary on Twitter
🆕 @EASLnews Clinical Practice Guidelines on the management of hepatic encephalopathy, in press‼️
Direct link👉https://t.co/MvNiPdfQg3@EASLedu @RautouE @mromerogomez @MontagneseSara @DebbieShawcros1#LiverTwitter pic.twitter.com/ebmA7ULGsD
— Journal of Hepatology (@JHepatology) June 17, 2022
WHO | COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades.
18 Jul, 2022 | 11:45h | UTCCommentaries:
WHO, UNICEF sound alarm over childhood immunization slide – CIDRAP
Commentary on Twitter (thread – click for more)
1⃣8⃣ million children did not receive a single vaccine in 2021 – the largest ↘️ in 29 years, due to:
🔸 #COVID19-related disruptions
🔸 emergencies
🔸 misinformation undermining vaccine acceptance & demandWHO & @UNICEF sound the alarm 🚨
🆕 data on global vaccine coverage ⬇️
— World Health Organization (WHO) (@WHO) July 14, 2022
Doctors tend to have unrealistic expectations of the success of multi-step medical procedures.
18 Jul, 2022 | 11:42h | UTCOriginal Study: Analysis of Physicians’ Probability Estimates of a Medical Outcome Based on a Sequence of Events – JAMA Network Open
Commentary on Twitter (thread – click for more)
This just out: Physicians do not logically/correctly estimate the probability of outcomes resulting from sequences of events – a thread. #conjunctionfallacy #probability #medicaldecisionmaking #clinicalreasoning #innumeracy #numeracy https://t.co/zGULPrdVBa @JAMANetworkOpen
— The Phlegmfighter (@phlegmfighter) June 27, 2022
Population-level risks of alcohol consumption by amount, geography, age, sex, and year | A systematic analysis for the Global Burden of Disease Study 2020.
18 Jul, 2022 | 11:39h | UTCCommentaries:
Alcohol is never good for people under 40, global study finds – The Guardian
Global study finds surprising results for alcohol consumption – CNN
No alcohol safe to drink, global study confirms – BBC
Commentary on Twitter (thread – click for more)
New #GBDStudy suggests alcohol consumption carries significant health risks and no benefits for young people; some older adults may benefit from drinking a small amount.
Find out more: https://t.co/nn3V68KNIX @IHME_UW pic.twitter.com/i5wz2AR94w
— The Lancet (@TheLancet) July 14, 2022
Network M-A | Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults.
18 Jul, 2022 | 11:41h | UTC
Review | Management of intermittent hemodialysis in the critically ill patient.
18 Jul, 2022 | 11:36h | UTC
Cohort Study | Reactogenicity of simultaneous COVID-19 mRNA booster and influenza vaccination.
18 Jul, 2022 | 11:34h | UTCCommentaries:
More (mostly mild) side effects when flu vaccine given with COVID booster – CIDRAP
Incidence, risk factors, natural history, and hypothesized mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
18 Jul, 2022 | 11:30h | UTCNews Release: New study updates evidence on rare heart condition after covid vaccination – BMJ Newsroom
Network M-A | Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer.
18 Jul, 2022 | 11:27h | UTC
Commentary on Twitter
Online first: Comparative effectiveness and risk of #preterm #birth of local #treatments for #cervicalintraepithelialneoplasia and stage IA1 #cervicalcancer: a systematic review and network meta-analysis https://t.co/APwtqyXJKO pic.twitter.com/GYuoroxRmw
— The Lancet Oncology (@TheLancetOncol) July 12, 2022
ESGE Position Paper | Reducing the environmental footprint of gastrointestinal endoscopy.
18 Jul, 2022 | 11:24h | UTC
Position Paper | Post-discharge and long-term follow-up after an acute coronary syndrome.
18 Jul, 2022 | 11:22h | UTC
Commentary on Twitter
Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper, by Sabouret et alhttps://t.co/yqPzc0q7ya@SABOURETCardio pic.twitter.com/vd1NTKKZ57
— Giuseppe Biondi-Zoccai (@gbiondizoccai) July 16, 2022
Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolemia.
18 Jul, 2022 | 11:18h | UTC
RCT | Aflibercept monotherapy or bevacizumab first for diabetic macular edema.
18 Jul, 2022 | 11:16h | UTCAflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Some insurance companies mandate a form of step therapy, which involves a trial of an inexpensive drug, bevacizumab, to treat diabetic macular edema. This trial compared two treatments: step therapy and a more expensive drug. #ASRS2022 https://t.co/gOhFTw1C1T pic.twitter.com/8uN9WgmtkD
— NEJM (@NEJM) July 14, 2022
RCT | Overall survival with Brentuximab Vedotin in stage III or IV Hodgkin’s lymphoma.
18 Jul, 2022 | 11:13h | UTCOverall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma – Mayo Clinic
M-A | Mid- to long-term clinical and echocardiographic effects of post-procedural permanent pacemaker implantation after transcatheter aortic valve replacement.
18 Jul, 2022 | 11:10h | UTC
RCT | Efficacy and safety of topical nitric oxide releasing Berdazimer gel in patients with molluscum contagiosum.
18 Jul, 2022 | 11:12h | UTC
Commentary on Twitter
This randomized, vehicle-controlled trial of molluscum contagiosum patients found the efficacy and safety of a once-daily application of berdazimer gel, 10.3% an experimental topical, nitric oxide-releasing medication. https://t.co/zKuA29BTPS
— JAMA Dermatology (@JAMADerm) July 13, 2022